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Programmed cell death is an important physiological response to many forms of cellular stress. The signaling cascades that result in
programmed cell death are as elaborate as those that promote cell survival, and it is clear that coordination of both protein- and lipid-mediated
signals is crucial for proper cell execution. Sphingolipids are a large class of lipids whose diverse members share the common feature of a long-
chain sphingoid base, e.g., sphingosine. Many sphingolipids have been shown to play essential roles in both death signaling and survival.
Ceramide, an N-acylsphingosine, has been implicated in cell death following a myriad of cellular stresses. Sphingosine itself can induce cell death
but via pathways both similar and dissimilar to those of ceramide. Sphingosine-1-phosphate, on the other hand, is an anti-apoptotic molecule that
mediates a host of cellular effects antagonistic to those of its pro-apoptotic sphingolipid siblings. Extraordinarily, these lipid mediators are
metabolically juxtaposed, suggesting that the regulation of their metabolism is of the utmost importance in determining cell fate. In this review, we
briefly examine the role of ceramide, sphingosine, and sphingosine-1-phosphate in programmed cell death and highlight the potential roles that
these lipids play in the pathway to apoptosis.
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Ongoing research in the field of cell death shows that the
mechanisms by which cells die are as complex (if not more
complex) than those by which cells survive. A common feature
of all physiologic forms of death is that they are programmed
events governed by specific biochemical pathways, hence the
name programmed cell death or PCD [1]. While PCD is driven
by complex pathways involving multiple players, it can be
broken down into three stages for pragmatic purposes: initiation,
commitment, and execution. The initiation step often occurs at
or in the proximity of the cellular compartment where the stress
is induced (Fig. 1) [2]. Disruption of calcium homeostasis at the
ER, for example, results in the activation of calcium-mediated
cell death [3]. Genotoxic stress in the nucleus induces p53 and
drives p53-activated pathways of cell death [4–7]. Lysosome
membrane disturbance causes the release of lysosomal pro-
teases, which have also been implicated in PCD [8,9]. Activation
of death receptors at the plasma membrane is another means of
inducing PCD, which may involve the downstream activation of
one or more organelle-mediated pro-apoptotic pathways [1,10].
Regardless of the initiation step, once a death signal is sensed by
specific sensors, biochemical pathways are activated, that
eventually converge onto the commitment step, or the point of
no return, which in many instances, occurs at the level of the
mitochondrion [11].
Once the death signal is relayed to the mitochondrion, the
organelle incurs a major change: mitochondrial membrane
permeabilization (MMP). MMP of the outer membrane causesFig. 1. Multiple pathways of cellular stress lead to MMP and apoptosis. Genotoxic str
MMP and the release of death factors from the mitochondrion. Cathepsins are release
the mitochondrion to promote MMP. ER stress can be manifested by dysregulat
mitochondria, leading to MMP. Finally, death receptor activation can lead to a multif
cleavage, mitochondrial disruption, and caspase activation.the release of several proteins from the intermembrane space
into the cytosol. Cytochrome c, the most studied of these
proteins, drives oligomerization of the adapter molecule APAF-
1, which then activates caspase 9, a key cysteine protease in the
mitochondrial pathway of cell death [12]. Caspase 9 can then
activate caspases 3 and 7, which belong to the execution phase
of PCD, since they cleave proteins that are vital to normal cell
function [13]. Another protein released from the mitochondrion
is Smac/Diablo, which binds to and inhibits cellular proteins
called IAPs (inhibitors of apoptosis) that normally keep
caspases from undergoing erratic activation in the healthy
state. Following release of cytochrome c and Smac, cells
display several features of apoptotic PCD, the most prominent
being chromatin condensation morphologically and cleavage of
PARP and externalization of phosphatidylserine (PS) biochemi-
cally. It should be noted that caspase 9 activation and PS
exposure on the outer leaflet of the cell membrane are ATP-
requiring processes, and that depletion of ATP from cells can
switch the death from an apoptotic form to a necrotic form [14].
In addition to the classical apoptotic form of PCD which
involves the activation of caspases, the mitochondrion harbors
other proteins, which upon release can drive alternative forms of
cell death that are entirely caspase-independent. Following
MMP, apoptosis inducing factor (AIF) [15] and endonuclease G
(Endo G) [16] translocate from the mitochondrion to the
nucleus and mediate apoptosis-like PCD, so called because they
cause loose chromatin condensation that is caspase indepen-
dent. HtrA2/Omi is also released from the mitochondrion and
has a dual role in cell death, one dependent on its ability toess activates p53 and “BH-3 only” proteins such as Noxa and Puma that promote
d during lysosomal stress and result in the cleavage of Bid, which translocates to
ion of calcium homeostasis and subsequent accumulation of calcium in the
aceted pathway that may involve lysosomal disruption, caspase 8-mediated Bid
2029T.A. Taha et al. / Biochimica et Biophysica Acta 1758 (2006) 2027–2036inactivate IAPs and cause caspase-dependent PCD, and another
due to its serine protease activity [17].
Since the mitochondrion constitutes an essential role in cell
death, it is not surprising that the cell has developed an entire
protein family to control the function of this organelle in the
healthy vs. the apoptotic state. Briefly, members of the Bcl-2
family of proteins belong to one of three different classes: the
Bcl-2 like survival factors, and these include Bcl-2 and Bcl-xL
(in addition to other less characterized members); the Bax-like
death factors, such as Bax and Bak; and the BH3-only death
factors, such as Noxa, Puma, Bid, Bad, and Bik [18]. The most
well characterized site of action of these proteins is the
mitochondrion itself, although actions at other organelles are
beginning to be proposed as well. Bcl-2-like proteins maintain
mitochondrial integrity and are regarded as guardians of this
organelle. In fact, overexpression of Bcl-2 and Bcl-xL rescues
cells from death induced by several stimuli that normally induce
MMP. Bax-like and BH3-only proteins, on the other hand,
compromise mitochondrial function and essentially mediate the
effect of several death inducers that cause MMP. Therefore, the
integrity of the mitochondrion (and the survival of the cell)
depends on a critical balance between the proapoptotic and the
antiapoptotic members of the Bcl-2 family. Of note is that Bcl-2
proteins not only are key players in apoptosis, but also in the
alternative forms of PCD, where MMP occurs. Classically,
apoptotic pathways have been described as either intrinsic or
extrinsic. The former indicates that the death signal is generatedFig. 2. Ceramide is a central mediator of many apoptotic pathways. Following geno
dependent or independent of p53. Signaling through the lysosomes involves increase
cathepsin D which can subsequently cleave and activate Bid. Another direct target of
prosurvival kinase Akt/PKB. Both PP2A and Akt/PKB regulate the Bax/Bcl-2 rheos
Bcl-2 and the mitochondrion is permeabilized. Death receptor activation can lead
lysosomes may also be activated downstream of death receptors, with both signals c
hydrolysis in mitochondria results in Bax translocation and MMP.from within the cell, such as in the case of genotoxic stress
causing cell death. The extrinsic pathway, on the other hand,
indicates that the death signal is generated by binding of a death
ligand to a cell surface receptor, which then activates the cas-
cade of apoptosis. MMP is essentially a key feature of the
intrinsic pathway. In cases where death ligands bind to their
surface receptors, cell death can proceed independent of the
mitochondrion and without MMP. Of note though is that the
extrinsic pathway often cross talks with the intrinsic pathway of
PCD, making the mitochondrion and the Bcl-2 proteins key
player also in death ligand-mediated PCD.
2. Ceramide and cell death
Given its central function, ceramide is the most studied sphin-
golipid species. Several lines of investigation have clearly
established this lipid as a mediator of the eukaryotic stress
response (Fig. 2) [19]. Ceramide accumulation can occur via: (i)
activation of de novo synthesis mediated by serine-palmitoyl
transferase (SPT) and ceramide synthase [20,21]; (ii) activation
of sphingomyelin hydrolysis [22,23]; (iii) inhibition of cera-
mide hydrolysis; and/or (iv) stimulation of glucosylceramide
hydrolysis or inhibition of its synthesis [24] (Fig. 1-1A). Some
agents activate a multitude of these pathways, such as ir-
radiation [25]. The effects of ceramide are pleiotropic, but for
the most part growth inhibiting. The molecule has been
implicated in differentiation [26,27], cell cycle arrest [28–30],toxic stress, ceramide accumulates, but it is still unclear whether the increase is
s in ceramide via aSMase. Ceramide can directly activate the lysosomal protease
ceramide is protein phosphatase 2A, which is known to negatively regulate the
tat; if the PP2A prevails, as is the case in ceramide signaling, Bax prevails over
to ceramide formation via nSMase and caspase 8-mediated cleavage of Bid;
onverging on MMP. Additionally, generation of ceramide from sphingomyelin
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induces cell cycle arrest through the dephosphorylation of the
Retinoblastoma gene product (Rb), activation of the cyclin
dependent kinase inhibitor p21, and inhibition of the cyclin
dependent kinase 2 (CDK2) [29,30,33]. These studies have
shown that ceramide is upstream of cell cycle regulators, and
that the generation of ceramide is necessary for growth arrest in
response to stimuli that induce this arrest. The elevation of
ceramide has also been shown to occur in senescent cells,
possibly via the activation of neutral sphingomyelinase
(nSMase) [34]. The senescent phenotype may be attributed to
a defect in the phospholipase D/protein kinase C (PLD/PKC)
pathway, and ceramide can inhibit both PLD and PKC [35–37].
One of the most studied roles of ceramide pertains to its
function as a proapoptotic molecule. The accumulation of
ceramide following treatment of cells with apoptotic agents has
implicated this lipid in the biological responses of these agents
[25]. Because of its apoptosis-inducing effects in cancer cells,
ceramide has been termed the “tumor suppressor lipid” [38].
Several studies have attempted to define further the specific role
of ceramide in the events of cell death. The tumor suppressor
protein p53, the Bcl-2 family of proteins and several protease
classes are all key components of the tumor response to stress
insults, and ceramide has been linked to each of these mediators.
Many studies, however, report variable associations among
these proteins and ceramide, suggesting that different cells have
dissimilar networks, and that deciphering the relevance of in
vitro findings to in vivo tumor behavior is far from understood.
2.1. Ceramide and p53
Several studies have generated conflicting data on the
relationship between ceramide and p53, which is virtually
dysfunctional in all human tumors.While some reports show that
p53 is upstream of ceramide in tumor stress responses [39,40],
other studies implicate p53 as a downstream target [41–43], yet
these latter studies utilize exogenous ceramide as the stress
inducer, whereas the former use agents that generate endogenous
ceramide. Still, other observations place ceramide and p53 in two
separate and independent pathways in the apoptotic process
[44,45]. In the latter case, treatment with chemotherapeutic
agents generates ceramide in p53+/+ as well as p53−/− cells. One
study has demonstrated that ceramide can be formed by acid
sphingomyelinase (aSMase) in response to genotoxic stress only
in cells lacking functional p53, suggesting that p53 can inhibit
aSMase activation and ceramide generation [46]. Studies by
Santana et al. also proposed a role for aSMase derived ceramide
in the apoptotic response and highlighted that the response is
different from that derived by p53 driven cellular responses [47].
Therefore, it remains unclear how ceramide and p53 are linked in
PCD and there appears to be variations in the link between the
two messengers in different cell death models.
2.2. Ceramide and the Bcl-2 Family
An equally wide array of studies has investigated the
relationship between ceramide and the Bcl-2 family of proteins,both following treatment with genotoxic and nongenotoxic
agents. The most studied connections pertain to Bcl-2 itself,
Bcl-xL, and Bax. The position of ceramide with respect to Bcl-2
is variably reported. A number of groups have shown that
ceramide is upstream of Bcl-2 in the apoptotic pathway since
Bcl-2 overexpression rescues from cell death induced by
ceramide [48] or by ceramidase inhibitors [49]. Moreover, El-
Assaad et al. have shown that Bcl-2 and Bcl-xL define two
different points of regulation of ceramide responses. While both
proteins rescue from TNF mediated cell death, only Bcl-xL
abrogates ceramide generation, while Bcl-2 does not, implying
a pathway where ceramide is downstream of Bcl-xL but
upstream of Bcl-2 [50]. Moreover, in C6 glioma cells, etoposide
induces ceramide formation by neutral sphingomyelinase
activation, which then increases the Bax/Bcl-2 ratio [51], and
in A549 cells, exogenous ceramide and endogenous ceramide
produced from gemcitabine treatment enhance the expression of
proapoptotic Bcl-x (BCl-xs) and caspase 9 splice variants,
demonstrating regulation of Bcl-2 family protein expression
levels and splicing patterns by the bioactive lipid [20]. On the
other hand, other studies have shown that Bcl-2 and or Bcl-xL
overexpression attenuates ceramide accumulation following
DNA damaging stimuli [52–54], thus implicating that Bcl-2 can
also act upstream of the lipid. Of note, however, is that many
studies of ceramide regulation in cell death have measured total
ceramide levels. Recently, it has become evident that the fatty
acid chain length of ceramides is an important determinant of
the biological effect mediated by the bioactive lipid. Marchesini
et al. reported that nSMase activation in confluent MCF-7 cells
causes cell cycle arrest but not apoptosis, and that this effect is
mediated by very long chain C24-ceramide species [55].
Kroesen et al., on the other hand, showed that cross linking of
the B-cell receptor generates C16-ceramide upstream of the
mitochondrion in a caspase independent manner, and that
inhibition of C16 ceramide generation rescues from cell death
[56]. In the same study, C24 ceramide is generated downstream
of mitochondrial dysfunction in a caspase dependent manner.
Therefore, it is clear from these data that not all ceramide
species generate the same responses, and that the different
biological effects caused by ceramide may be mediated by
distinct molecular species of the lipid. Moreover, it should be
noted that nonmitochondrial sites of action have been reported
for the Bcl-2 family of proteins, warranting that conclusions
made with respect to these proteins may not always be extra-
polated to the mitochondrion.
The connection between ceramide and Bax has also been
reported by several studies. One study has shown that Bax
overexpression does not affect ceramide production in response
to etoposide [54], yet ceramide treatment in a prostate and
colorectal cancer cell line induces apoptosis only when Bax is
overexpressed, suggesting a link between the lipid and the
protein [57]. Furthermore, Birbes et al. have recently shown that
localized production of ceramide in the mitochondrion induces
Bax oligomerization and drives cell death [58]. This study is in
agreement with the observation that ceramide treatment of
isolated mitochondria potentiates the Bax-mediated induction
of mitochondrial permeability transition (MPT) [59]. Further-
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acidic sphingomyelinase (aSMase) mediates Bax conforma-
tional change and induces MMP in vivo and in vitro [60].
Ceramide has also been implicated in oocyte death as its levels
increase in oocytes prior to increases in Bax protein levels and
the induction of apoptosis [61]. Endothelial cells of Bax and
aSMase deficient mice were also recently shown to have higher
resistance to radiation induced cell death, indicating that cera-
mide generation by aSMase may also be important in micro-
vasculature homeostasis in addition to cancer cell homeostasis
[62,63].
Ceramide may regulate Bcl-2 and Bax simultaneously by
modulating their phosphorylation states. It was established
several years ago that Bcl-2, whose phosphorylation by PKCα
at serine 70 is required for its anti-apoptotic function, becomes
dephosphorylated in response to ceramide [64,65]. Recent work
suggests that the ceramide-activated protein phosphatase PP2A
may inhibit Bcl-2 via its dephosphorylation and proteasomal
degradation [66]. On the other hand, Bax may also be regulated
via PP2A, because Xin et al. showed that Bax is dephos-
phorylated following ceramide treatment in a PP2A-dependent
manner [67]. Dephosphorylation of Bax was associated with its
conformational change and subsequent release of cytochrome c
from the mitochondria. Therefore, these studies display a
proximal connection between ceramide, Bcl-2, and Bax, and
implicate that ceramide may be a regulator of Bcl-2 family
members and their control over cell death pathways.
2.3. Ceramide and the mitochondrion
In addition to its link to the Bcl-2 family of proteins, an
intimate connection is becoming more evident between
ceramide and the mitochondrion. First, several enzymes
involved in sphingolipid metabolism have been identified in
subcellular fractions containing mitochondria. Bionda et al.
have reported ceramide synthase and reverse ceramidase
activities in the mitochondria and/or ER-related mitochondria
associated membranes (MAMs) of rat liver [68]. Ceramide
synthase has also been partially purified from bovine liver
mitochondria [69]. Furthermore, a mammalian ceramidase
localized in a similar compartment has recently been cloned
[70], and sphingosine kinase type 2 has been described as a
BH3-only like protein [71]. Therefore, more evidence is
pointing towards machinery for sphingolipid biosynthesis at
the level of the mitochondrion. The localization of these
activities has been suggestive of the importance of generating
the right lipid in the right place to induce its specific effects.
In vitro experiments have revealed that ceramide can induce
several changes in isolated mitochondria. Gudz et al. have
shown that C2-ceramide can inhibit oxidative phosphorylation
by interfering with the electron transport system at the level of
complex III [72]. Ceramide also increases the permeability of
the outer mitochondrial membrane to several proteins, including
cytochrome c [73]. A recent study reported the ability of
ceramide to enhance permeability of the inner mitochondrial
membrane, via action on the permeability transition pore (PTP)
and the electrogenic proton channel, which enhances the releaseof solutes into the cytosol [74]. Perhaps ceramide can mediate
multiple different pathways to release pro-apoptotic factors
from the mitochondrion. Lorusso and colleagues showed that
ceramide could induce cytochrome c release from isolated
mitochondria in both a PTP-dependent and independent manner
[75]. Ceramide also maintains cytochrome c in an oxidized
state, a status which appears to be necessary for reducing
mitochondrial oxygen consumption, dissipating the mitochon-
drial membrane potential (Δψm), and releasing calcium from
the mitochondria [76]. Hence, all these studies point to a direct
effect of ceramide on the mitochondrion.
While the above in vitro studies provide a direct link
between ceramide and the mitochondrion, studies clearly
defining the role that ceramide plays in cells have been very
scarce, mostly owing to the difficulty in tracking the localization
of ceramide. It is clear from the study by Zhang et al. that the
topology of ceramide generation is essential for the lipid to
mediate its downstream effects, since generation of the lipid
at the plasma membrane is insufficient to induce cell death,
whereas its generation within the cell is [77]. Further inves-
tigation into organelle-specific sphingomyelin hydrolysis has
shown that only ceramide generation at the mitochondrion can
drive cell death, whereas its formation in other organelles does
not [78]. These studies demonstrate that once ceramide reaches
the mitochondrion, it can induce the effects that the bioactive
lipid exerts on the isolated organelle, making the in vitro obser-
vations relevant in vivo as well.
2.4. Ceramide and proteases
Other important components of PCD pathways are the
proteases, which fall under two general categories: caspases
and non-caspase proteases, both of which can be activated by
ceramide. While the mediators linking initiator death signals to
the activation of the mitochondrion are still poorly character-
ized, the sequence of events involved in the activation of
caspases downstream of the mitochondrion is fairly well
established. Extensive work shows that ceramide accumulates
in apoptotic cells prior to the activation of execution caspases,
but downstream of initiator caspases [40,79,80]. Ceramide
also activates the non-caspase protease, cathepsin D [81] (Fig.
2), a mediator of cell death in several p53-dependent death
model systems [82]. The formation of ceramide via acidic sphin-
gomyelinase has also been shown to mediate the cleavage of
Bid and downstream caspase activation in response to TNF
[83]. Also, ceramide generation by aSmases has been suggested
to mediate cell death by caspase dependent and independent
mechanisms depending on the death stimulus [84].
2.5. Ceramide and autophagy
The role of ceramide in cell death pathways has been
recently extended to encompass autophagy or Type II PCD (in
contrast to apoptosis or Type I PCD). C2-ceramide upregulates
the autophagy genes BNIP3 [85] and Beclin-1 [86] and de novo
ceramide synthesis inhibitors can attenuate the induction of
autophagy by Tamoxifen in MCF-7 cells [86]. Therefore, the
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PCD may be gaining more ground.
3. Sphingosine and cell death
Several studies have pointed to a specific role for sphin-
gosine in the induction of cell death independent of ceramide
(Fig. 3A) [87]. In HL-60 cells, both ceramide and sphingosine
accumulate before the features of cell death appear, yet their
order in the pathway of cell death may be different [88]. While
inhibition of caspases with Z-VAD-fmk rescues from apoptosis
induced by both ceramide and sphingosine, z-IETD-fmk, the
caspase-8 inhibitor and Z-AAD-fmk, the granzyme B inhibitor,
are only effective against sphingosine but not ceramide [88].
The ceramide synthase inhibitor fumonisin B1 also does not
inhibit sphingosine induced apoptosis in HL-60 and Jurkat T
cells, indicating that the conversion of sphingosine to ceramide
may not be required for the induction of cell death by sphin-
gosine [88,89]. In MCF-7 cells, however, FB1 or D-MAPP, an
inhibitor of alkaline ceramidase, are both effective in reducing
apoptosis caused by exogenous sphingosine, suggesting that
conversion to a ceramide intermediate may be important for the
execution of sphingosine effects in some cells [90]. A recent
study has reported that apoptosis induction by FTY720 is due to
the ability of this compound to inhibit SK in vitro and
accumulate sphingosine in vivo [91]. Concentrations of exoge-
nous sphingosine that produce similar levels of intracellular
sphingosine as FTY720 cause apoptotic features as well, im-
plicating sphingosine as an active molecule in cell death [91].
The mechanisms mediating sphingosine-driven cell death
are multiple, and in some cases do not coincide with those
mediating ceramide death pathways [90]. Both lipids have been
shown to induce apoptosis in U937 human monoblastic
leukemia cells, yet ceramide-associated lethality involves the
strong activation of JNK and weak inhibition of ERK, whereas
sphingosine-driven death is associated with weak JNK activa-
tion and strong ERK inhibition [92]. Sphingosine can also
inhibit Akt/Protein kinase B (PKB), and overexpression ofFig. 3. Sphingosine and S1P in apoptosis. (A) Sphingosine mediates cell death throug
via SDK1, which leads to Bax activation through inhibition of 14-3-3 proteins. (B) S
ERK, and NO. Ceramide-induced death may also be inhibited by S1P through the iconstitutively active myristoylated Akt partially rescues from
sphingosine-induced death [93]. Sphingosine-mediated apop-
tosis has been shown to occur via caspase-dependent pathways.
Sphingosine can induce Bid cleavage, mitochondrial cyto-
chrome c release as well as the activation of downstream
effector caspases 3 or 7 and the cleavage of PARP [89,90,94].
The involvement of the mitochondrial pathway of PCD is
further illustrated by the effects of sphingosine on the Bcl-2
family of proteins. Studies have shown that sphingosine can
reduce the expression levels of Bcl-2 and Bcl-xL, major
gatekeepers of the mitochondrion [95,96]. Sphingosine-induced
cell death has also been proposed to occur even in Bcl-2
transfected cells and to involve cleavage of Bax, and the
association of the cleaved (and full length) Bax with Bcl-2
[97].
Sphingosine can also exert its effects via regulation of PKC.
Initially, the bioactive lipid was found to inhibit PKC [98,99],
an important prosurvival signal in the cell [100]. Recently, a
sphingosine-dependent protein kinase (SDK1) has been de-
scribed as a truncated version of PKCδ (a proapoptotic PKC),
which forms by a caspase-3 dependent cleavage of the full-
length PKCδ [101]. While full-length PKCδ is inhibited by
sphingosine and DMS, SDK1 activity is stimulated by the two
lysophospholipids [101]. Among the substrates for SDK1 are
the 14-3-3 proteins, specifically isoforms β, η, and ζ but not τ
or σ [102]. 14-3-3 proteins are chaperones for several cellular
proteins, including members of the Bcl-2 family, such as Bax
[103,104] and Bad [105–108] (Bad requires phosphorylation
itself to bind to 14-3-3 [109]). Phosphorylation of 14-3-3 is
often associated with the release of the proapoptotic proteins,
allowing them to exert their cell killing effects. Even though
inhibition of PKC is a mechanism of sphingosine-mediated cell
death, sphingosine can still induce apoptosis in cell systems
were PKC is stimulated [94], suggesting the existence of
sphingosine-responsive PKC-insensitive pathways of cell
death. Multiple sphingosine activated kinases (other than
SDK1) have also been suggested to exist, yet the identification
of these awaits further studies [110].h the inhibition of the prosurvival factors PKC and Akt/PKB and induces death
1P inhibits apoptosis by activating prosurvival factors such as Akt/PKB, NF-κB,
nactivation JNK or other factors that promote PCD.
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way, sphingosine can also exert effects on other organelles. It
has been shown that HeLa cells exposed to ceramide undergo
massive Golgi fragmentation and inhibition of β1 integrin
glycosylation and transport to the cell surface prior to the
induction of apoptosis [111]. Exogenous sphingosine results in
similar effects as exogenous ceramide, suggesting that the
ceramide effects are due to its conversion to sphingosine in the
Golgi complex [111]. The resulting loss of integrin signaling
then leads to cell death by anoikis [111]. Almost a decade before
that, the work of Rosenwald and Pagano also suggested a role
for ceramide in slowing transport of viral glycoprotein across
the Golgi apparatus, which was also disrupted by the lipid as
well [112]. In that study, sphingosine had no effect, suggesting
that the lipids may have slightly variable effects in different
cells. There appears to be specific lipid mediated responses
though because stereoisomers of ceramide were unable to cause
changes in the Golgi complex [111].
Phytosphingosine, a saturated close relative of sphingosine
having a hydroxyl group at the carbon-4 position (Fig. 1-4), is
also a mediator of cell death. In combination with gamma
irradiation, phytosphingosine enhances apoptosis of radiation
resistant T cells by promoting reactive oxygen species (ROS)
formation and AIF release, in a caspase independent manner
[113]. The mechanism of phytosphingosine-induced cell death
has been described to involve the inhibition of ERK, which
drives caspase-8 activation, and the stimulation of p38 MAPK,
which mediates Bax translocation and mitochondrial apoptosis
[114].
4. SK, S1P, and cell death
Of particular interest in the biology of sphingolipids are the
antagonistic roles that ceramide and sphingosine, on one hand,
and sphingosine-1-phosphate, on the other, appear to exert in a
variety of cells. Ceramide and sphingosine mediate apoptosis,
cell cycle arrest, and differentiation, whereas S1P promotes
proliferation, survival, and inhibition of apoptosis [115]. These
findings have lead to the so-called sphingolipid rheostat which
proposes that the relative levels of these lipids (especially in
response to stressors or growth stimuli) are important
determinants of cell fate [115].
One of the earliest observations implicating S1P as a pro-
growth lipid was the ability of PDGF and fetal calf serum to
induce growth via the activation of sphingosine kinase and the
formation of S1P, then called an intracellular second messenger
[116]. Several growth stimuli were then shown to activate the
SK/S1P pathway, which in turn appears to be required for the
activation of downstream signaling by these stimuli. In addition,
overexpression of SK1 in itself decreases ceramide and sphin-
gosine levels and increases S1P [117], a sphingolipid conver-
sion that is associated with enhanced proliferation, G1-S
transition, and increased DNA synthesis [118].
The role of SK and S1P in PCD has come from several
studies showing that these two mediators can attenuate death
and growth inhibitory effects caused by several stressors. As
mentioned earlier, ceramide accumulates under many forms ofstress. A key study consolidating the “sphingolipid rheostat” is
the report that S1P can inhibit PCD induced by ceramide [119].
In fact, the killing effects of several agents that enhance
ceramide formation in the cell are significantly attenuated when
SK is stimulated by an agonist or by overexpression of the
enzyme. Conversely, knockdown of SK1 causes cellular
accumulation of ceramide, activation of the intrinsic pathway,
and leads to cell death [120].
The mechanisms by which SK and S1P exert their proli-
ferative and survival effects appear to involve several key
players in cell survival and cell death pathways (Fig. 3B). SK
activation and S1P production mediate the resistance of
HUVEC cells to TNF induced proapoptotic effects through
the activation of NF-kB, a known anti-apoptotic transcription
factor [121]. Other pro-survival mediators shown to be activated
by SK/S1P include Akt [122], nitric oxide [123], and ERK. SK
overexpression can also inhibit apoptotic pathways, as shown in
PC12 cells, where the enzyme rescues from apoptosis through
attenuation of JNK activation by serum starvation or ceramide
[124]. In leukemia cells, S1P inhibits the release of mitochon-
drial proapoptotic factors caused by serum deprivation, anti-
Fas, TNF, or ceramide [125]. Interestingly, the SK/S1P pathway
appears also to be involved in anoikis. Nakamura et al. have
shown that cells dying by anoikis have lower SK activity than
adherent cells, and that inhibition of SK in the adherent cells
causes cell death, whereas supplementation of S1P rescues
nonadherent cells from anoikis [126].
SK is the only degradative pathway for the clearance of
ceramide and sphingosine from the cell. The reaction catalyzed
by sphingosine phosphate lyase (SPL) is the only irreversible
catalytic reaction in the sphingolipid pathway in which the
sphingosine backbone is hydrolyzed. Thus, the lyase reaction is
the exit point of sphingolipids to the general cellular lipid pool,
and any sphingolipid to be hydrolyzed has to be converted to
S1P first, highlighting indirectly the importance of SK. There-
fore, one straight forward explanation for the ability of SK
overexpression to attenuate cell death caused by stressors that
elevate ceramide may be due to increased clearance of a toxic
lipid. However, the ability of S1P itself to overcome ceramide
effects, also suggests that enhanced S1P production by SK
activation is itself important for these biological effects. Even
more interesting is the potential for S1P to feedback on de novo
ceramide biosynthesis. Van Echten-Deckert et al. have shown
that the conversion of sphingosine to S1P can inhibit SPT
activity [127]. Moreover, in SPPase-1 overexpressing cells, S1P
is dephosphorylated and ceramide synthesis is enhanced [128],
suggesting that SK/S1P not only modulate clearance of a toxic
lipid (ceramide), but they may also reduce its synthesis. These
studies therefore, broaden the mechanisms by which SK/S1P
can modulate cell death.
The regulation of SK1 has also been shown to occur in the
apoptotic pathway by a mechanism involving proteases. DNA
damage and TNF both induce the loss of SK1 through a
mechanism that is sensitive to inhibitors of the lysosomal
protease cathepsin B [129,130]. Given the emerging role of the
lysosome in PCD, these data add a further dimension to the
mechanism of SK1 regulation, potentially implicating the
2034 T.A. Taha et al. / Biochimica et Biophysica Acta 1758 (2006) 2027–2036enzyme as a potential mediator of lysosome-driven pathways of
cell death.
Despite the majority of studies demonstrating anti-apoptotic
roles for SK and S1P, cloning of SK2 has yielded unexpected
results. Although it produces the same lipid (S1P) as SK1, SK2
appears to be proapoptotic and growth inhibitory. SK2 has a
putative BH3-only motif, which may be involved in its
proapoptotic effects through the mitochondrial pathway [71].
Moreover, SK2 localizes in the nucleus of some cells under
certain conditions, where it may inhibit DNA synthesis [131].
Whether these effects are dependent on S1P production or on
the activity of SK2 remains to be determined.
5. Concluding remarks
Although the studies addressing the role of sphingolipids in
cell death are numerous, many of the specific functions that
these mediators regulate are still elusive. The evidence
implicating ceramide in cell death and SK1 and S1P in cell
survival is consistent, yet there appears to be differences in the
mechanisms of cell signaling in different cell types as well as
the signals generated by different stimuli. This suggests a
versatile role for these lipids in cell function that can potentially
be tailored for a therapeutic advantage. The sphingolipid
rheostat appears to be a critical point in determining cell fate.
Once more specific molecular targets are identified for the
various lipid mediators, the exact mechanisms of action may
become even clearer, and such interactions can be exploited for
more efficient cell killing.
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